These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9654593)

  • 1. Drug resistance in ovarian cancer - the role of p53.
    Petty R; Evans A; Duncan I; Kurbacher C; Cree I
    Pathol Oncol Res; 1998; 4(2):97-102. PubMed ID: 9654593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary.
    Daponte A; Guidozi F; Tiltman AJ; Marineanu A; Taylor L
    Anticancer Res; 1999; 19(3B):2387-9. PubMed ID: 10472362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
    Kupryjańczyk J; Szymańska T; Madry R; Timorek A; Stelmachów J; Karpińska G; Rembiszewska A; Ziółkowska I; Kraszewska E; Debniak J; Emerich J; Ułańska M; Płuzańska A; Jedryka M; Goluda M; Chudecka-Głaz A; Rzepka-Górska I; Klimek M; Urbański K; Breborowicz J; Zieliński J; Markowska J
    Br J Cancer; 2003 Mar; 88(6):848-54. PubMed ID: 12644821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
    Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
    Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.
    Mano Y; Kikuchi Y; Yamamoto K; Kita T; Hirata J; Tode T; Ishii K; Nagata I
    Eur J Cancer; 1999 Aug; 35(8):1214-9. PubMed ID: 10615232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma.
    Lustosa SA; Logullo A; Artigiani R; Saad SS; Goldenberg A; Matos D
    Acta Cir Bras; 2005; 20(5):353-7. PubMed ID: 16186958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma.
    Masding J; Sarkar TK; White WF; Barley VL; Chawla SL; Boesen E; Rostom AY; Menday AP
    Br J Obstet Gynaecol; 1990 Apr; 97(4):342-51. PubMed ID: 2187525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group.
    Keldsen N; Madsen EL; Havsteen H; Kamby C; Laursen L; Sandberg E
    Gynecol Oncol; 1998 May; 69(2):100-2. PubMed ID: 9625618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
    Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
    J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.
    Bold RJ; Hess KR; Pearson AS; Grau AM; Sinicrope FA; Jennings M; McConkey DJ; Bucana CD; Cleary KR; Hallin PA; Chiao PJ; Abbruzzese JL; Evans DB
    J Gastrointest Surg; 1999; 3(3):263-77. PubMed ID: 10481119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.